Rhapsido FDA Approval History
FDA Approved: Yes (First approved September 30, 2025)
Brand name: Rhapsido
Generic name: remibrutinib
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Urticaria
Rhapsido (remibrutinib) is a kinase inhibitor indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment.
Development timeline for Rhapsido
| Date | Article |
|---|---|
| Sep 30, 2025 | Approval FDA Approves Rhapsido (remibrutinib) for the Treatment of Chronic Spontaneous Urticaria |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.